Furkan Bahar/X
Aug 3, 2026, 12:30
Furkan Bahar: Thrombotic and Hemorrhagic Risk Profiles in Advanced Melanoma – Targeted vs Immune Combination Therapies
Furkan Bahar, Research Fellow at Dana Farber, shared a post on X about a recent article he and his colleagues co-authored, published in RPTH, adding:
“Excited to share our new paper, published in Research and Practice in Thrombosis and Haemostasis!
We compared VTE and bleeding risk between BRAF/MEK inhibitors and ipilimumab/nivolumab combination therapy in patients with advanced melanoma.”
Title: Venous Thromboembolism and Bleeding in Advanced Melanoma: A Propensity-Matched Cohort Analysis Comparing First-Line Immunotherapy and Targeted Therapy
Authors: Furkan Bahar, Lauren O’Loughlin, Soravis Osataphan, Hollis Viray, Reed E. Drews, Rushad Patell
Stay updated with Hemostasis Today.
-
Aug 3, 2026, 13:42Immune Thrombocytopenia: Moving Beyond Platelet Counts Toward Durable Remission
-
Aug 3, 2026, 13:28Aboo Shama Khan: Pulmonary Embolism – A Medical Emergency Every Nurse Must Recognize
-
Aug 3, 2026, 13:08Ashwin Patel: Evaluating Red Cell Function Post-Treatment in SCD Patients
-
Aug 3, 2026, 13:03Mohamed El Belghiti Alaoui: The Promise of AAV Gene Therapy in Hemophilia A
-
Aug 3, 2026, 12:44Replaying the CSL Symposium on Gene Therapy Durability in Haemophilia – EAHAD
-
Aug 3, 2026, 12:43Shinta C: Takeda Marks a Milestone in Hemophilia Care
-
Aug 3, 2026, 12:37Deepak Kumar Dasmohapatra: Honored for Contributions to Transfusion Medicine and Immunohematology by the Governor of Chhattisgarh
-
Aug 3, 2026, 12:28Tayyaba Iftikhar: When Platelets Talk to Cancer Cells
-
Aug 3, 2026, 12:19Heparin Beyond Anticoagulation in Sepsis – JTH